Or at the Dockets Management Staff between 9Ī.m. FDA–2019–D–0297 for “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”Īll submissions received must include the Docket No.Mail/Hand Delivery/Courier (for written/paper submissions):ĭockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. Submit written/paper submissions as follows:
0 Comments
Leave a Reply. |